The novel nitric oxide synthase inhibitor 7-ni troindazole (7 -NI) is relatively specific for the neuronal isoform of the enzyme and in this study we have used this compound to investigate the physiological role of perivas cular nitric oxide-containing nerves in the cerebrovascu lar bed. Following injection of7-NI (25 or 50 mg/kg, i.p.), cerebral blood flow and glucose utilization were mea sured in the conscious rat using the fully quantitative [14C]iodoantipyrine and 2-[14C]deoxyglucose techniques, respectively. Neither dose of the drug produced any change in arterial blood pressure, confirming a lack of effect upon the endothelial isoform of the enzyme, al though there was a pronounced decrease in heart rate ( -28% by 10 min postinjection). Throughout the brain 25 mg/kg 7-NI i.p. resulted in decreases in blood flow of between -20% in the hippocampus and -58% in the substantia nigra. Increasing the dose to 50 mg/kg resulted in a further generalized decrease, to almost -60% in
There is a growing body of evidence that cerebral blood vessels are innervated by nitric oxide (NO) producing neuronal processes at all levels of the cerebrovascular tree, from the circle of Willis and the principal cerebral arteries which branch from it (Nozaki et aI., 1993; Suzuki et aI., 1993; Yoshida et aI., 1993) to pial arteries (Estrada et aI., 1993; Nozaki et aI., 1993; Yoshida et aI., 1993) and pen etrating intracerebral arterioles (ladecola et aI., parts of the tha!amus and hippocampus, but in every an imSiI this higher dose of 7-NI also produced randomly distributed areas of relative hyperaemia, which were most commonly found in those areas where the most in tense hypoperfusion was otherwise in evidence. Despite these changes in blood flow, in all but a very few areas of the brain no significant decrease in glucose use was mea sured at either of the two doses of 7 -NI. Thus despite the greater specificity of 7-NI for neuronal nitric oxide syn thase, the cerebrovascular effects of the drug in vivo are very similar to that reported for the arginine analogues. However, these data do suggest that nitric oxide releasing neurones in the brain may have an important role to play in the regulation of cerebral blood flow. Key Words: Cerebrovascular control-Local cerebral blood flow-Local cerebral glucose utilization-Nitric oxide-7-Nitroindazole. 19930; Regidor et aI., 1993) . There is also some ev idence that NO-releasing nerves may induce va sodilatation (Lee and Sarwinski, 1991) and in vivo might regulate the tone of large cerebral arteries (Toda and Okamura, 1991) , but as yet it is unclear whether NO released from neurones innervating the small resistance vessels might provide a mechanism by which cerebral tissue perfusion could be regu lated.
Arginine analogues, which have been widely used to investigate the role of NO in cerebrovascular control (Tanaka et aI., 1991; Kozniewski et aI., 1992; Dirnagl et aI., 1993) , lack specificity in their site of action and appear to be equally effective in inhibiting endothelial and neuronal nitric oxide syn thase (NOS) . In contrast, the novel NOS inhibitor, 7-nitroindazole (7-Nl), is relatively specific for the constitutive isoform of the enzyme found within the neurones of the brain (Moore et a!., 1993a,b) . Al though basal levels of NOS activity are highest in the cerebellum, treatment with 7-NI reduces neuro nal NOS activity equally (by between 30 and 40%) in the cerebellum, neocortex, and hippocampus of intact rat brain (Babbedge et a!., 1993) , with signif icant reductions persisting for at least 4 h following an intraperitoneal injection (MacKenzie et aI., 1994) . In contrast, the inhibition of NOS by arginine analogues is much longer lasting and is thought to be irreversible (Dwyer et a!., 1991) . Although in rat 7-NI inhibits cerebellar NOS with a potency (lCso = 0.9 ± 0.1 fLM) equal to that of � -nitro-L arginine methyl ester (L-NAME; ICso = 0.9 ± 0.08 fLM) (Babbedge et a!., 1993) , there are differences between species in this regard. In mouse, 7-NI is almost twice as potent as in the rat ( l Cso = 0.47 ± 0.01 fLM), whilst L-NAME is equipotent in both species (Moore et a!., 1993a) . Moreover, in mouse the effect of 7-NI is much shorter lived and is totally dissipated by 120 min following an intraperitoneal injection (Moore et a!., 1993b) .
There is some evidence that 7-NI may inhibit en dothelial NOS derived from supernatant of bovine aortic homogenates (Babbedge et a!., 1993) , but in isolated rabbit aortic rings 7-NI neither induces constriction nor alters acetylcholine-induced dilata tion (Moore et a!., 1993b) . Moreover, the lack of pressor response in any species so far examined suggests that any endothelial effects have little if any physiological significance in vivo. Thus the ap parent specificity of 7-NI for neuronal NOS makes it a useful tool with which to study the possible influence of perivascular neuronal release of NO in the control of cerebrovascular calibre. However, neuronal NO production may also alter cerebral function (Bredt et a!., 1990) via interaction with glu tamatergic neurotransmission (Garthwaite et a!., 1989; Hoyt et a!., 1992; Lipton et a!., 1993) and it must be borne in mind that manipulation of NO synthesis in the brain may have metabolic conse quences (either stimulatory or inhibitory) which could affect cerebral blood flow. The purpose of the present study was to investigate the effects of intra peritoneal injection of 7-NI upon local cerebral blood flow (LCBF) and glucose utilization (LCMR glr) in the conscious rat. An abstract of this work has been published previously (Kelly et a!., 1994a) .
MATERIALS AND METHODS

Animal preparation
A total of 34 male Sprague-Dawley rats (250-300 g) was used in this study. On the day of the experiment the an imals were anaesthetized with halothane (maintained at 1% in a mixture of 70% nitrous oxide and 30% oxygen) and polythene cannulae were inserted into both femoral arteries, to allow sampling of arterial blood and measure ment of arterial blood pressure, and both femoral veins for injection of radiolabelled tracers. An intraperitoneal cannula was inserted via a trocar into the abdominal space, secured with suture at the insertion site, and led caudally to lie with the femoral cannulae, to which it was also secured. Following the application of a loose-fitting plaster cast to the pelvis and hind limbs, the rats were supported on a weighted platform to which the plaster was secured with adhesive tape. The rats were allowed to recover from the effects of the anaesthesia for at least 2 h before any further experimental manipulation. Core tem perature, blood pressure, and heart rate were monitored continuously throughout the experimental period, and blood gas status and plasma glucose levels were mea sured immediately before drug treatment and again before the initiation of blood flow or glucose use measurements.
Preparation of 7-NI for injection 7-NI (Lancaster Synthesis Ltd., Morecombe, England) was suspended in oil (12.5 mg/ml), taken into solution with mild sonication, and kept warm until use. At the end of the recovery period, the rats were injected with 7-NI at doses of 25 or 50 mg/kg via the indwelling intraperitoneal cannula. These doses cover the range used previously in functional studies of7-NI activity (Moore et aI., 1993a,b) . Control animals were injected with vehicle alone. The measurements of LCMRglc or LCBF were initiated at 30 and 40 min after the injection of7-NI, respectively. In rat brain maximal NOS inhibition is manifest within 30 min following the intraperitoneal injection of 7-NI, and the tl/2 for the response is of the order of 4 h (MacKenzie et aI., 1994) .
Measurement of LCBF
CBF was measured in 19 rats using the fully quantita tive [14Cjiodoantipyrine autoradiographic technique (Sakurada et aI., 1978) . The tracer (35 ILCi in 0.5 ml sa line) was infused intravenously at a constantly accelerat ing rate over 45 s. During the infusion period, blood was allowed to flow freely from one of the arterial cannulae and timed samples were collected intermittently onto pre weighed filter discs. Subsequently, the timing of each sample was corrected to take into account the delay in troduced by the flow characteristics of the cannula tub ing. At 45 s, the animals were killed by decapitation, and the brains dissected intact and frozen in precooled 2-me thylbutane ( -45°C) within 2 to 3 min of death. The filter discs were placed into scintillation vials and reweighed to determine the sample size before being prepared for liq uid scintillation analysis.
Measurement of LCMR g lc
Glucose use was measured in 15 rats using the fully quantitative 2-[ 14Cjdeoxyglucose autoradiographic tech nique. The measurement was initiated with a 30-s intra venous injection of tracer (40 ILCi in 0.75 m1 saline). Over the subsequent 45 min, a total of 14 timed arterial blood samples was collected at predetermined intervals and centrifuged to separate plasma. Aliquots of each plasma sample were taken for the determination of 14C concen trations (20 ILl) and glucose levels (10 ILl) by liquid scin tillation analysis and semiautomated glucose oxidase as say (Beckman), respectively. At the end of the measure-ment period the rats were killed by decapitation and the brains prepared as for blood flow experiments.
Preparation and analysis of autoradiograms
Semiserial cryostat sections (20 11m) were cut in the coronal plane from each brain, with three consecutive sections collected from every 200 11m of tissue. Autora diograms were prepared by application of the sections to x-ray film (SB-5; Kodak) in a lighttight cassette for 7 days. The resultant autoradiographic plates were anal ysed using a computer-based imaging system (Cambridge Instruments Quantimet 97 0). Isotope concentrations in brain sections were determined by densitometric analysis relative to precalibrated 14C-containing standards (Amer sham, UK) and LCMRglc or LCBF was calculated using the operational equations for the techniques (Sokoloff et aI., 1977 ; Sakurada et aI., 1978) .
Statistical analysis
Data are presented as mean:!: SD. Statistical analyses of the results from physiological measurements and inde pendent LCBF and LCMRglc data were performed by analysis of variance followed by a post hoc Scheffe test to allow multiple comparisons. Acceptable levels of signifi cance were set at p < 0.05. To provide an initial assess ment of differences between treatment groups in the re lationship of LCBF to LCMRglc in each of 25 brain areas included in this study, the ratios of mean LCBF to mean LCMRg1c were derived for each structure examined. More rigorous statistical analysis of the relationship was performed by repeated-measures analysis of variance on the log transform of the data sets (McCulloch et aI., 1982) using the BMDP/PC90 computerized statistical package (program 2V) (lennrich et aI., 1990) .
RESULTS
Physiological variables
Neither of the two doses of 7-NI had any signif icant effect upon rectal temperature, arterial pcoz, P02' pH, or plasma glucose levels compared to ve hicle-injected controls. In keeping with previous re ports ( Moore et aI., 1993a,b) , 7-NI had no effect upon mean arterial blood pressure (MABP) at any time throughout the study (Fig. 1) . The drug was not, however, totally devoid of cardiovascular ef fects. Following treatment with both 25 and 50 mg/ kg 7-NI, there was a relatively rapid and significant decrease in heart rate, which persisted throughout the rest of the experimental period ( Fig. 1 ).
LCBF
At a dose of 25 mg/kg, 7-NI reduced LCBF throughout the brain, with decreases from mean control values ranging from a minimum of -21 % in hippocampal CAl to a maximum of -58% in the substantia nigra (Table 1) . Only in the CAl and frontoparietal cortex ( -23%) did the response fail to reach statistical significance. In general terms the higher dose of 7-NI (50 mg/kg) produced further widespread reductions in LCBF (Table 1) , which were significantly different from control in all brain regions analysed. Although LCBF at 50 mg/kg was not significantly different from that at 25 mg/kg, and in some instances the effect was actually greater at the lower dose (e.g., within the basal ganglia; Table 1), the overall response was more homogeneous, ranging from a minimum of -40% in the entorhinal cortex to -59% in parts of the thalamus and hip pocampus. However, against this background of generalized reductions in perfusion, localized areas of relative hyperperfusion were clearly evident in every animal in the higher dose group. These areas were most usually found unilaterally within any given animal but, otherwise, appeared to be ran domly distributed, with no clear pattern in terms of either the structural or the vascular anatomy of the brain. Quantification on an individual-animal basis revealed that in the majority of cases these areas were hyperaemic only relative to the rest of the brain (in which LCBF was generally reduced), but in a few instances the hyperaemia was absolute, reaching blood flow values which exceeded the con- trol means by >25%. Those areas where hyperper fusion could be visibly detected as "hot spots" on the autoradiographic images were excluded from the general analysis.
LCMR g lc
The effects of 7-NI upon LCMR g lc were both qualitatively and quantitatively dissimilar to the ef fects upon LCBF (Table I) . Thus, in contrast to the widespread reductions in LCBF following drug treatment, only one area (lateral habenula) showed any significant change in LCMR g lc at 25 mg/kg ( -16%), and although at the higher dose significant decreases were measured in seven cortical and tha lamic regions, the effect upon LCMR g lc (ranging from -15% in the parietal cortex to -30% in the habenula) was less pronounced than the effect upon LCBF. There was no evidence of focal hyperme tabolism in any of the 7-NI-treated animals.
The relationship between LCBF and LCMR g lc
Decreases in LCBF in response to 7-NI in the absence of any changes of similar magnitude in LC MR g lc had profound effects upon the relationship between brain tissue perfusion and underlying me tabolism. In control rats, there was clearly an asso ciation between mean LCBF and mean LCMR g lc in the brain as a whole (r = 0.861) and the overall ratio between blood flow and glucose use, as illustrated by the slope of the best-fitting straight line, was 2.01 ( Fig. 2a ). In those animals treated with 7-NI, the relationship between LCBF and LCMR g lc remained largely intact at both doses of the drug (r = 0.812, r = 0.775) ( Fig. 2a ). However, the overall ratios between LCBF and LCMR g lc (m = 1.43, m = 1.19) were lower than in the control group (Fig. 2a) . Ex amining the brain areas individually, the flow metabolism ratio was found to decrease in all 25 brain areas in rats treated with 25 mg/kg (Table 1, Fig. 2b ) and by -25% or more in all but five areas (Fig. 2b) . Although further decreases in the ratio were evident at the higher dose of 7-NI, it is inter esting to note that in the basal ganglia and associ ated motor areas of thalamus, the ratio was higher in the 50 mg/kg group than in the 25 mg/kg group. Although this can be explained in part by the de crease in glucose utilization in these areas, it should be noted that in the neocortex, where there were significant decreases in LCMR g lc at 50 mg/kg (which were not evident at the lower dose), the ratio was also decreased at this dose. Repeated-measures analysis of variance confirmed that the resetting of the flow-metabolism relationship was significant (p < 0.01). LCMRglc in 25 brain areas of rats injected intraperitoneally with either 25 or 50 mg/kg 7-NI or vehicle alone. a: In the brain as a whole there was a clear relationship between blood flow and metabolism in both groups (r = correlation coefficient), but the equations defining the best-fitting straight line for the datum points show that the gradient (ratio) was decreased in the 7-NI-treated groups, in dicating a downward resetting of the overall flow-metabolism relationship in the brain. b: 4
Line of Identity
Flow-metabolism ratios derived from mean data for each of the 25 brain areas in vehicle treated animals plotted against the ratios similarly derived for 7-NI-treated animals. At both doses of the drug, all datum points lie below the line of identity, indicating that the ratio is decreased in all areas of the 7-NI treated rat brain. In all but five areas of the brain from rats treated with 25 mg/kg 7-NI, and one area from rats treated with 50 mgl kg, the ratio is reduced by more than 25% from that of vehicle controls. Vehicle Control LCBF I LCMRglu Ratio
DISCUSSION
In a number of previous studies, decreases in basal LCBF have been described following NOS inhibition by a variety of � -substituted arginine analogues, including � -nitro-L-arginine (NOLAG) (Kovach et a!., 1992; Wang et a!., 1992; Dirnagl et a!., 1993) , � -monomethyl-L-arginine (Tanaka et a!., 1991; Kozniewski et a!., 1992) , and L-NAME (Goads by et a!., 1992; Northington et a!., 1992; Prado et a!., 1992; Iadecola et a!., 1993b; Pelligrino et a!., 1993) . Where studies have included a mea sure of cerebral metabolic activity, it has been found that these decreases in LCBF occur in the absence of any underlying change in glucose utili zation (Macrae et a!., 1993; Kelly et a!., 1994b) . There are, however, some inconsistencies in the lit erature. For example, no change in regional CBF could be detected in anaesthetized dogs following inhibition of NO synthesis with L-NAME, despite J Cereb Blood Flow Metab. Vol. 15. No.5. 1995 clearly reduced flow in other organs of the body (Sonntag et a!., 1992) , and in both anaesthetized and conscious rats, neither L-NAME nor NOLAG had any effect upon basal CBF (Iadecola, 1992; Wang et a!., 1993) . Data from anaesthetized cats adds a fur ther level of complexity by describing a regional heterogeneity in the response of CBF to NOLAG, with cerebellum and hindbrain being markedly af fected whilst cortical flow was unchanged (Kovach et aI., 1992) . One possible explanation for these di chotomies could rest with the profound hyperten sive effects of these drugs arising from peripheral vasoconstriction. Although we have previously shown in the conscious rat that treatment with L-NAME alters the upper limit of autoregulation (Kelly et a!., 1994b) , and thus provides protection against hypertension, this may not be universally true under all experimental conditions. The compli cation of peripheral cardiovascular effects of NOS inhibition can be overcome by the direct appli-cation of the inhibitors to the brain (Irikura et aI., 1994) . However, whilst this approach confirms the effects of systemically administered arginine analogues in reducing CBF, direct injection of L-NAME also produces a paradoxical decrease in NOS enzyme expression (Arbuthnott et aI., 1994) , which could in itself account for the decrease in CBF.
A new class of indazole-based NOS inhibitors has recently been developed, of which 7-NI is currently the most potent. In cerebellar homogenates 7-NI produces NOS inhibition with an IC50 in the low micromolar range (Moore et aI., 1993a) . Following the administration of 7-NI in vivo, NOS activity in the brain is inhibited by between 30 and 40% (Babbedge et aI., 1993) , but at doses of up to 50 mg/kg it has no effect upon blood pressure (Moore et aI., 1993b) . Thus it appears that 7-NI is selective for the neuronal isoform of the NOS enzyme, whilst having little or no effect upon the endothelial iso form. In the present study 7-NI produced wide spread reductions in LCBF in the absence of any changes in LCMR g lc. Although the homogeneity of these changes does not reflect the heterogeneous distribution of NOS in the rat brain (F6stermann et aI., 1990; Vincent and Kimura, 1992) , it does reflect the uniformity in the effects of 7-NI in reducing NOS activity to an equal degree (30-40%) in all brain areas, albeit from different basal levels of ac tivity (Babbedge et aI., 1993) .
Given recent reports of an endothelium-and NOS-independent relaxation of vascular smooth muscle in vitro (Medhurst et aI., 1994) , the speci ficity of the indazole derivatives requires further investigation. Further in vitro studies have revealed that 7-NI binds to the heme group of the NOS mol ecule, where it competes directly with L-arginine (Klatt et aI., 1994) . If 7-NI has a wider capacity to block a variety of iron-dependent systems (as do other NOS inhibitors) (Peterson et aI., 1992) , this could be a possible source of vasoactivity which is independent of NOS inhibition. The fact that 7-NI has no effect upon the peripheral circulation, how ever, suggests that such effects may become mani fest only in vivo under limited physiological condi tions, if at all. Such questions relating to the spec ificity of 7-NI for neuronal, as opposed to endothelial NOS, may easily be addressed in future with the development of mice in which the gene encoding for the neuronal isoform of NOS has been disrupted by gene targeting (O'Dell et aI., 1994) . Such models are already proving useful to charac terize the contributions made by neuronal and en dothelial NO in the development of ischaemic dam age (Huang et aI., 1994) .
In this study we have confirmed in conscious rats that 7-NI has no significant effect upon systemic blood pressure. The drug is not, however, totally devoid of cardiovascular effects, producing a rela tively rapid and pronounced reduction in heart rate. It is not possible from this study to determine the mechanism underlying this phenomenon, but given the putative specificity of 7-NI for the neuronal NOS isoform, it is intriguing to speculate that NO might play an important role in the regulation of central cardiovascular control centres. Alterna tively, NOS inhibition has been shown to decrease stress-induced release of catecholamines (Hal briigge et aI., 1991) , and if our rats had been stressed, a decrease in heart rate would be one of the manifestations to be expected from this effect. However, there was no evidence from the physio logical variables that these animals were unduly stressed by the experimental procedures. In partic ular, there ,was no indication of hyperglycemia (which is a sensitive index of elevated circulating catecholamines) in this study, and in previous stud ies using the same preparation we have shown that plasma corticosterone levels are no different from basal nonstressed levels (Seckl et aI., 199 1) .
The resetting of the flow-metabolism relationship induced by 7-NI is very similar to the effect of L-NAME (Macrae et aI., 1993; Kelly et aI., 1994b) , but given the specificity of 7-NI for neuronal NOS, the effects observed in this study are possibly the result of inhibition of perivascular neuronal NO synthesis and release. If such an interpretation is correct, then it must be concluded that intrinsic perivascular NO-releasing neurones have an impor tant role to play in the regulation of basal cerebro vascular tone and the control of CBF. Given that lesion of the sphenopalantine ganglion has no effect upon resting LCBF (Seylaz et aI., 1989) , it is un likely that the effects described here are due to NO released from this extrinsic source (Iadecola et aI., 1993a; Nozaki et aI., 1993) .
The complex patterns of blood flow evident at the 50 mg/kg dose of 7-NI are difficult to explain. It is possible that the profound reductions in LCBF elic ited by the drug, with very little change in underly ing metabolic demand, produced focal increases in the concentrations of vasodilator metabolites which ultimately allowed homeostatic mechanisms to be reestablished. However, the levels of oligaemia ob served in this study are no more intense than those found by us, and others, following L-NAME treat ment, and yet there is no evidence of a similar phe nomenon with this or any other arginine analogue. Dilatation in response to 7-NI has been reported from preconstricted dog middle cerebral artery in vitro (Medhurst et aI., 1994) , as discussed previ ously, and it would appear from this study that given the appropriate physiological conditions, a similar phenomenon may become manifest in the cerebral circulation in vivo. Exactly what these conditions might be, and whether they vary in dif ferent parts of the cerebrovascular bed, remains to be determined.
In conclusion, the results of this study clearly indicate that the cerebrovascular sequelae of 7-NI treatment in the conscious rat are very similar to those observed following � -substituted arginine analogues. These results are consistent with the hy pothesis that NO, synthesised and released from neuronal (as opposed to endothelial) sources in the brain, has the potential to regulate CBF. The in volvement of perivascular NO-releasing neurones in this process deserves closer scrutiny.
